Artnet1h
Nan Goldin’s Berlin Exhibition Embroiled in Symposium Controversy
A symposium taking place on the same weekend of the show of Nan Goldin at the Neue Nationalgalerie has drawn criticism online ...
Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines
Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...
The Art Newspaper17h
From neon installations to an animatronic bear, here's what not to miss this Turin Art week
Turin Art week may be focused around Artissima, Italy’s oldest art fair, but there's must-see exhibitions to found across the ...
BioNTech started at buy, Moderna at hold by Berenberg
Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.
Moderna initiated with a Hold at Berenberg
Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...
API management company Kong raises $175M to provide connectivity for next-generation AI
API technology startup Kong Inc. said today it has closed on a bumper $175 million late-stage round of funding, bringing its ...
Loves by Domus23h
The great Nan Goldin exhibition now in Berlin
This Will Not End Well” is the incredible retrospective that the Neue Nationalgalerie dedicates to one of the most important ...
Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
S&P 500 Gains and Losses Today: Uber Falls as Trump Eyes Looser Self-Driving Rules
The S&P 500 added 0.4% on Monday, Nov. 18, kicking off a trading week that will feature a highly anticipated earnings report ...
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential
Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.
Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler
Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good entry point for investors, according to Piper Sandler. Piper Sandler, which reiterated Overweight rating on Moderna, ...